Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 7 Gy Clear all
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer

NCT00047008
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
195
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

NCT01401062
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fresolimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca

NCT02453737
View directory record Official record
Conditions
Breast Cancer
Interventions
Brachytherapy APBI, 3D-CRT (photon) APBI, Proton APBI
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen

NCT01328496
View directory record Official record
Conditions
Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy
Interventions
Preparative Regimen
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 4 Interventional

Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients

NCT00882089
View directory record Official record
Conditions
Breast Cancer
Interventions
Contura catheter
Device
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

NCT00186888
View directory record Official record
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

NCT02314403
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Insufficiency
Interventions
Belatacept, ATG, Rituximab, Total Body Irradiation, Thymic Irradiation, Combined Bone Marrow/Kidney Transplantation
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 31, 2026, 2:04 PM EDT
Recruiting Phase 1 Interventional

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

NCT07139990
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions
Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

NCT02318771
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IV Lung Cancer, Stage IV Skin Melanoma
Interventions
Radiation Therapy (RT), MK-3475
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

NCT00711412
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery
Drug · Radiation · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

NCT00551525
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy, Samarium 153
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Recruiting Phase 2 Interventional

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

NCT05491226
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Pembrolizumab, Radiation Therapy, Axatilimab
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

NCT00026208
View directory record Official record
Conditions
Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
Interventions
Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
2
States / cities
Stanford, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

NCT05538533
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
46 Gy Radiation Therapy, 40 Gy Radiation Therapy, 35 Gy Radiation Therapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

NCT03077243
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Non-Operative Management and Early Response Assessment in Rectal Cancer

NCT03904043
View directory record Official record
Conditions
Adenocarcinoma of the Lower Rectum
Interventions
Radiation therapy, FOLFOX regimen, CAPOX regimen
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy

NCT03953976
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Intensity modulated radiation therapy (IMRT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer

NCT00068237
View directory record Official record
Conditions
Head and Neck Cancer, Radiation Toxicity, Xerostomia
Interventions
salivary gland transfer, Post-operative radiation therapy
Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 31, 2026, 2:04 PM EDT
Recruiting Phase 1 Interventional

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

NCT06492954
View directory record Official record
Conditions
Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions
Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab
Procedure · Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

NCT02282371
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab, BYL719, IMRT (Intensity-Modulated Radiation Therapy)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

NCT00660218
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
paclitaxel poliglumex, cetuximab, radiation therapy (IMRT or 3D-CRT)
Drug · Biological · Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

NCT03007732
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, SD-101, Leuprolide acetate, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
David Oh
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858
View directory record Official record
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 31, 2026, 2:04 PM EDT